** Shares of drug developer Biohaven rise 2.7% to $39.5 premarket
** BHVN says its experimental drug, BHV-1300, reduced targeted Immunoglobulin G, a type of antibody, by more than 60% in an early-stage clinical trial
** BHVN partnered with Ypsomed to develop an autoinjector for BHV-1300, co says
** All 15 brokerages rate the stock "buy" or higher; their median PT is $63 - LSEG
** As of last close, stock has fallen ~10% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。